Pharmaceutical

Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I

The company has initiated a Phase I trial of its bivalent RSV and hMPV-targeting vaccine called VXB-241.

Sep 24, 2024 - 04:00
Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I
The company has initiated a Phase I trial of its bivalent RSV and hMPV-targeting vaccine called VXB-241.
Read the original article

Tags:

Previous Article

Teva touts safety profile of once monthly schizophrenia therapy

Next Article

Pharmaceutical Wholesalers for the Pharmaceutical Industry

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Roche wins first-line approval for PI3K inhibitor combo in breast cancer

Roche wins first-line approval for PI3K inhibitor combo...

Oct 12, 2024

Opinion: Current heat warning systems are woefully inadequate in an age of climate change

Opinion: Current heat warning systems are woefully inad...

Apr 11, 2023

CDC recommends rationing of RSV shot due to shortages

CDC recommends rationing of RSV shot due to shortages

Oct 24, 2023